Endymed (Israel) Performance
| ENDY Stock | 295.00 1.00 0.34% |
On a scale of 0 to 100, Endymed holds a performance score of 9. The firm shows a Beta (market volatility) of -0.17, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Endymed are expected to decrease at a much lower rate. During the bear market, Endymed is likely to outperform the market. Please check Endymed's mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether Endymed's price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Endymed are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Endymed sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 7.3 M | |
| Total Cashflows From Investing Activities | 382 K |
Endymed |
Endymed Relative Risk vs. Return Landscape
If you would invest 21,780 in Endymed on September 29, 2024 and sell it today you would earn a total of 7,720 from holding Endymed or generate 35.45% return on investment over 90 days. Endymed is generating 0.8239% of daily returns and assumes 6.6364% volatility on return distribution over the 90 days horizon. Simply put, 59% of stocks are less volatile than Endymed, and 84% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Endymed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Endymed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Endymed, and traders can use it to determine the average amount a Endymed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1241
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ENDY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.64 actual daily | 59 59% of assets are less volatile |
Expected Return
| 0.82 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Endymed is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Endymed by adding it to a well-diversified portfolio.
Endymed Fundamentals Growth
Endymed Stock prices reflect investors' perceptions of the future prospects and financial health of Endymed, and Endymed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Endymed Stock performance.
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0385 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 1.85 M | |||
| Shares Outstanding | 13.76 M | |||
| Price To Book | 0.70 X | |||
| Price To Sales | 1.52 X | |||
| Revenue | 21.78 M | |||
| EBITDA | 3.2 M | |||
| Cash And Equivalents | 5.02 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 463 K | |||
| Debt To Equity | 7.10 % | |||
| Book Value Per Share | 1.04 X | |||
| Cash Flow From Operations | 4.63 M | |||
| Earnings Per Share | 0.74 X | |||
| Total Asset | 19.6 M | |||
| Retained Earnings | (12 M) | |||
| Current Asset | 9 M | |||
| Current Liabilities | 4 M | |||
About Endymed Performance
By analyzing Endymed's fundamental ratios, stakeholders can gain valuable insights into Endymed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Endymed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Endymed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Endymed Ltd, a medical technology company, designs, develops, and commercializes energy based medical aesthetic treatment systems for the professional and consumer markets worldwide. Endymed Ltd was founded in 2007 and is based in New York, New York. ENDYMED LTD operates under Medical Devices classification in Israel and is traded on Tel Aviv Stock Exchange.Things to note about Endymed performance evaluation
Checking the ongoing alerts about Endymed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Endymed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Endymed is way too risky over 90 days horizon | |
| Endymed appears to be risky and price may revert if volatility continues | |
| About 58.0% of the company shares are held by company insiders |
- Analyzing Endymed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Endymed's stock is overvalued or undervalued compared to its peers.
- Examining Endymed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Endymed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Endymed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Endymed's stock. These opinions can provide insight into Endymed's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Endymed Stock analysis
When running Endymed's price analysis, check to measure Endymed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endymed is operating at the current time. Most of Endymed's value examination focuses on studying past and present price action to predict the probability of Endymed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endymed's price. Additionally, you may evaluate how the addition of Endymed to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |